AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.
Financial Results:
Astrazeneca Pharma India Ltd reported Revenues for Q4FY25 of ₹1,000.00 Crores up from ₹974.00 Crore year on year, a rise of 2.67%.
Total Expenses for Q4FY25 of ₹914.00 Crores up from ₹905.00 Crores year on year, a rise of 0.99%.
Consolidated Net Profit of ₹86.00 Crores from -₹2.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹1.58, from -₹0.48 in the same quarter of the previous year.
